Zhi G, Huang D X, Yang X S
Zhonghua Nei Ke Za Zhi. 1989 Sep;28(9):534-6, 572.
Clinical and hemodynamic studies were carried out for the purpose of evaluating the effects of enalapril in the treatment of chronic heart failure. Enalapril 10-20 mg was given once to 10 patients with moderate to severe congestive heart failure (coronary 6, hypertensive heart disease 2 and idiopathic congestive cardiomyopathy). Hemodynamic studies were done on the first day after drug administration and the same dose was maintained for 2 weeks. The results showed a decrease of mean BP of 18.29% (P less than 0.01), CVP 40.4% mPAP 23.9%, PCWP 41.2%, SVR 39.9% and PVR 41.3% respectively (P less than 0.001). Cardiac index increased 44.16% (P less than 0.001). The therapeutic action lasted more than 24 hours after a single dose. No further drop of BP was found weeks later, 6 patients in NYHA class III and 2 in class IV improved to class II. No severe side effects were found. The results showed that enalapril is well tolerated after a single dose and its therapeutic action lasts 2 weeks with improvement both in hemodynamics and subjective symptoms.
为评估依那普利治疗慢性心力衰竭的效果，进行了临床和血流动力学研究。对10例中度至重度充血性心力衰竭患者（冠心病6例、高血压性心脏病2例、特发性充血性心肌病2例）单次给予依那普利10 - 20mg。在给药后的第一天进行血流动力学研究，并维持相同剂量2周。结果显示平均血压下降18.29%（P<0.01），中心静脉压下降40.4%，平均肺动脉压下降23.9%，肺毛细血管楔压下降41.2%，体循环阻力下降39.9%，肺血管阻力下降41.3%（P<0.001）。心脏指数增加44.16%（P<0.001）。单次给药后治疗作用持续超过24小时。数周后血压未进一步下降，6例纽约心脏协会（NYHA）心功能Ⅲ级患者和2例Ⅳ级患者改善为Ⅱ级。未发现严重副作用。结果表明，依那普利单次给药耐受性良好，其治疗作用持续2周，血流动力学和主观症状均有改善。
